Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

Table 2 Multiple linear regression analysis between insulin sensitivity and secretion indices and glucose control parameters before randomization

	HbA_1c			Fasting plasma glucose			AUC_glu
	β	95% CI	P	β	95% CI	P	β	95% CI	P
DI₁₂₀	−0.784	(−0.053,-0.014)	0.001*	−0.426	(−1.053,-0.148)	0.011*	−0.525	(−14.088,-2.496)	0.006*
HOMA-β (%)	0.005	(−0.010,0.011)	0.979	−0.507	(−0.752,-0.262)	<0.001*	−0.348	(−7.040,-0.759)	0.016*
Insulinogenic index₃₀ (pmol/mmol)	0.341	(−0.001,0.014)	0.075	0.211	(−0.038,0.303)	0.124	0.016	(−2.074,2.296)	0.919
HOMA-IR	−0.068	(−0.223,0.165)	0.764	0.484	(2.168,11.302)	0.005*	0.128	(−38.411,78.513)	0.492
MISI	0.270	(−0.111,0.488)	0.210	0.037	(−6.204,7.882)	0.811	−0.021	(−95.634,84.672)	0.903

Adjusted for age, gender, body mass index, and disease duration. *P < 0.05.
AUC_glu, area under curve of glucose in 120 min; DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index;
HOMA-IR, homeostasis model assessment insulin resistance index; MISI, Matsuda insulin sensitivity index.

ISSN: 1758-5996